Mark Agulnik

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren, John M. Kane, Mark Agulnik et al. · Journal of the National Comprehensive Cancer Network · 2022 · 1.1K citations · Full text

Surgical Oncology, Tumoral Pathology, Soft Tissue Sarcoma +15

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 582 citations

Surgical Oncology, Oncology, Soft-tissue Sarcoma +7

Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer

Ezra E.W. Cohen, Theodore Karrison, Masha Kocherginsky et al. · Journal of Clinical Oncology · 2014 · 558 citations · Full text

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Wan‐Teck Lim, Boon Cher Goh, Edwin P. Hui et al. · Journal of Clinical Oncology · 2018 · 455 citations · Full text

Metastatic Npc, Oncology, Antitumor Activity +15

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

Mark Agulnik, Jessica Lee Yarber, Scott H. Okuno et al. · Annals of Oncology · 2012 · 384 citations · Full text